Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia
NCT03038022Phase 2Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of resmetirom in heterozygous familial hypercholesterolemia (HeFH), sponsored by Madrigal Pharmaceuticals. Started Feb 2017; status: completed.
02
Drugs
resmetirom
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT03038022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038022.